Genetic conjugation of components in two pneumococcal fusion protein vaccines enhances paediatric mucosal immune responses (Q39037134)

8 September 2017

title

Genetic conjugation of components in two pneumococcal fusion protein vaccines enhances paediatric mucosal immune responses (English)

1 reference

8 September 2017

5

1 reference

8 September 2017

Caroline Pope

1

1 reference

8 September 2017

Elizabeth H Oliver

2

1 reference

8 September 2017

Jiangtao Ma

3

1 reference

8 September 2017

Claire Langton Hewer

4

1 reference

8 September 2017

Adam Finn

6

1 reference

8 September 2017

language of work or name

English

0 references

publication date

17 February 2015

1 reference

8 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

8 September 2017

volume

33

1 reference

8 September 2017

issue

14

1 reference

8 September 2017

page(s)

1711-1718

1 reference

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Multinational study of pneumococcal serotypes causing acute otitis media in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Structural basis of pore formation by the bacterial toxin pneumolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Characterization of the interactions of the pneumolysoid, Δ6 PLY, with human neutrophils in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Mucosal immunization with recombinant fusion protein DnaJ-ΔA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Essential role of domain 4 of pneumolysin from Streptococcus pneumoniae in cytolytic activity as determined by truncated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Interleukin-17A mediates acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

The NLRP3 Inflammasome Is Differentially Activated by Pneumolysin Variants and Contributes to Host Defense in Pneumococcal Pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.02.012

1 reference

8 September 2017

1 reference